RU2017126229A - Композиции и способы лечения гиперкалиемии - Google Patents
Композиции и способы лечения гиперкалиемии Download PDFInfo
- Publication number
- RU2017126229A RU2017126229A RU2017126229A RU2017126229A RU2017126229A RU 2017126229 A RU2017126229 A RU 2017126229A RU 2017126229 A RU2017126229 A RU 2017126229A RU 2017126229 A RU2017126229 A RU 2017126229A RU 2017126229 A RU2017126229 A RU 2017126229A
- Authority
- RU
- Russia
- Prior art keywords
- paragraphs
- binding polymer
- microns
- cross
- potassium binding
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 68
- 239000000203 mixture Substances 0.000 title claims 63
- 229920000642 polymer Polymers 0.000 claims 525
- 239000011591 potassium Substances 0.000 claims 412
- 229910052700 potassium Inorganic materials 0.000 claims 412
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 406
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 119
- 239000002245 particle Substances 0.000 claims 94
- 238000004132 cross linking Methods 0.000 claims 55
- 239000008194 pharmaceutical composition Substances 0.000 claims 45
- 125000003118 aryl group Chemical group 0.000 claims 41
- 230000008961 swelling Effects 0.000 claims 41
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 39
- 159000000007 calcium salts Chemical class 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 23
- 239000012798 spherical particle Substances 0.000 claims 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 238000005342 ion exchange Methods 0.000 claims 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 16
- 239000003431 cross linking reagent Substances 0.000 claims 12
- 208000002682 Hyperkalemia Diseases 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 150000001721 carbon Chemical group 0.000 claims 9
- TUMCWFMHZOUPDA-UHFFFAOYSA-N 2-ethylsulfanyl-1,3-benzothiazol-6-amine Chemical compound C1=C(N)C=C2SC(SCC)=NC2=C1 TUMCWFMHZOUPDA-UHFFFAOYSA-N 0.000 claims 8
- 239000004376 Sucralose Substances 0.000 claims 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 8
- 229960004543 anhydrous citric acid Drugs 0.000 claims 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 8
- 235000019408 sucralose Nutrition 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 229920000609 methyl cellulose Polymers 0.000 claims 4
- 239000001923 methylcellulose Substances 0.000 claims 4
- 239000000178 monomer Substances 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 239000004408 titanium dioxide Substances 0.000 claims 4
- 239000000230 xanthan gum Substances 0.000 claims 4
- 229920001285 xanthan gum Polymers 0.000 claims 4
- 229940082509 xanthan gum Drugs 0.000 claims 4
- 235000010493 xanthan gum Nutrition 0.000 claims 4
- QWFMDSOYEQHWMF-UHFFFAOYSA-N 2,3-bis(ethenyl)benzenesulfonic acid Chemical group OS(=O)(=O)C1=CC=CC(C=C)=C1C=C QWFMDSOYEQHWMF-UHFFFAOYSA-N 0.000 claims 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims 3
- 229960002796 polystyrene sulfonate Drugs 0.000 claims 3
- 239000011970 polystyrene sulfonate Substances 0.000 claims 3
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical group OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 235000009499 Vanilla fragrans Nutrition 0.000 claims 2
- 244000263375 Vanilla tahitensis Species 0.000 claims 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims 2
- 239000007968 orange flavor Substances 0.000 claims 2
- 235000019629 palatability Nutrition 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 235000010199 sorbic acid Nutrition 0.000 claims 2
- 239000004334 sorbic acid Substances 0.000 claims 2
- 229940075582 sorbic acid Drugs 0.000 claims 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims 2
- 235000012141 vanillin Nutrition 0.000 claims 2
- 239000004971 Cross linker Substances 0.000 claims 1
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 claims 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 claims 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 claims 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 230000035923 taste sensation Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/745—Polymers of hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/16—Organic material
- B01J39/18—Macromolecular compounds
- B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F212/02—Monomers containing only one unsaturated aliphatic radical
- C08F212/04—Monomers containing only one unsaturated aliphatic radical containing one ring
- C08F212/06—Hydrocarbons
- C08F212/08—Styrene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F212/02—Monomers containing only one unsaturated aliphatic radical
- C08F212/04—Monomers containing only one unsaturated aliphatic radical containing one ring
- C08F212/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by heteroatoms or groups containing heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/22—Esters containing halogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F257/00—Macromolecular compounds obtained by polymerising monomers on to polymers of aromatic monomers as defined in group C08F12/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/34—Introducing sulfur atoms or sulfur-containing groups
- C08F8/36—Sulfonation; Sulfation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/44—Preparation of metal salts or ammonium salts
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2800/00—Copolymer characterised by the proportions of the comonomers expressed
- C08F2800/10—Copolymer characterised by the proportions of the comonomers expressed as molar percentages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicinal Preparation (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Treatment Of Water By Ion Exchange (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096447P | 2014-12-23 | 2014-12-23 | |
| US62/096,447 | 2014-12-23 | ||
| PCT/US2015/067460 WO2016111855A1 (en) | 2014-12-23 | 2015-12-22 | Compositions and methods for treating hyperkalemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017126229A true RU2017126229A (ru) | 2019-01-28 |
Family
ID=55229846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017126229A RU2017126229A (ru) | 2014-12-23 | 2015-12-22 | Композиции и способы лечения гиперкалиемии |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9655921B2 (enExample) |
| EP (1) | EP3236940B1 (enExample) |
| JP (3) | JP6821571B2 (enExample) |
| KR (1) | KR102674230B1 (enExample) |
| CN (1) | CN107406548B (enExample) |
| AR (1) | AR103250A1 (enExample) |
| AU (1) | AU2015375390B2 (enExample) |
| BR (1) | BR112017013264A2 (enExample) |
| CA (1) | CA2971725C (enExample) |
| ES (1) | ES2800167T3 (enExample) |
| IL (1) | IL252603A0 (enExample) |
| MX (1) | MX373216B (enExample) |
| NZ (1) | NZ732542A (enExample) |
| RU (1) | RU2017126229A (enExample) |
| TW (1) | TW201628631A (enExample) |
| WO (1) | WO2016111855A1 (enExample) |
| ZA (1) | ZA201703771B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2800167T3 (es) * | 2014-12-23 | 2020-12-28 | Ardelyx Inc | Composiciones y métodos para tratar hiperpotasemia |
| US9433640B2 (en) | 2014-12-23 | 2016-09-06 | Ardelyx, Inc. | Compositions and methods for treating hyperkalemia |
| MX2020001412A (es) | 2017-08-04 | 2020-08-03 | Ardelyx Inc | Compuestos y métodos para tratar la hiperpotasemia. |
| JP7735185B2 (ja) | 2019-02-07 | 2025-09-08 | アルデリックス， インコーポレイテッド | 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体 |
| US12280144B2 (en) | 2019-12-19 | 2025-04-22 | Zaki Yusuf | Gel compositions for mitigation of burn injuries, kits containing the gel compositions, and associated methods |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3785864A (en) | 1970-07-23 | 1974-01-15 | Boehringer Mannheim Gmbh | Process for the chromatographic separation of multi-component mixtures containing glucose |
| GB1561395A (en) | 1976-02-26 | 1980-02-20 | Beecham Group Ltd | -lactam antibiotic |
| CA1166413A (en) | 1980-10-30 | 1984-05-01 | Edward E. Timm | Process and apparatus for preparing uniform size polymer beads |
| JPS57193414A (en) * | 1981-05-25 | 1982-11-27 | Sekisui Chem Co Ltd | Preparation of remedy for hypercalcemia |
| WO1999020285A1 (en) * | 1997-10-16 | 1999-04-29 | Sanwa Kagaku Kenkyusho Co., Ltd. | Gel preparations containing polystyrenesulfonate |
| US6280717B1 (en) * | 1998-07-31 | 2001-08-28 | Nikken Chemicals Co., Ltd. | Cation exchange resin preparation |
| JP3596742B2 (ja) * | 1998-07-31 | 2004-12-02 | 日研化学株式会社 | 陽イオン交換樹脂製剤 |
| US6270755B1 (en) * | 1999-05-13 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders |
| DE112005000725B4 (de) * | 2004-03-30 | 2017-12-21 | Relypsa, Inc. (n.d.Ges.d. Staates Delaware) | Verfahren und Zusammensetzungen zur Behandlung von Ionen-Ungleichgewichten |
| GB2430368B (en) * | 2004-03-30 | 2009-08-26 | Ilypsa Inc | Methods and compositions for treatment of ion imbalances |
| US8192758B2 (en) * | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
| WO2008039358A2 (en) * | 2006-09-30 | 2008-04-03 | Capricorn Pharma Inc. | Resin-complex granulation for water-soluble drugs and associated methods |
| DE102007050971B4 (de) * | 2007-03-14 | 2014-12-31 | BLüCHER GMBH | Verfahren zur Herstellung von Hochleistungsadsorbentien auf der Basis von Aktivkohle mit hoher Meso- und Makroporosität, Hochleistungsadsorbentien und deren Verwendung |
| CN103919792B (zh) * | 2008-08-22 | 2018-03-09 | 瑞立普萨公司 | 交联阳离子交换聚合物、组合物及在治疗方法高钾血症中的应用 |
| WO2010022381A1 (en) | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| US20110028412A1 (en) | 2009-08-03 | 2011-02-03 | Cappellos, Inc. | Herbal enhanced analgesic formulations |
| ES2364683B1 (es) | 2009-12-29 | 2012-08-08 | Bioibérica S.A. | Disacáridos sulfatados para el tratamiento de enfermedades neurodegenerativas y/o neurovasculares. |
| CA2824391A1 (en) * | 2011-01-10 | 2012-07-19 | Sorbent Therapeutics, Inc. | Compositions comprising crosslinked cation-binding polymers and a base, uses thereof |
| TWI605837B (zh) | 2011-01-27 | 2017-11-21 | Kowa Co Ltd | Pharmaceutical composition containing water-insoluble drug and pharmaceutical preparation |
| ES2441468B1 (es) | 2012-08-03 | 2014-11-13 | Laboratorios Rubió, S.A. | Composición farmacéutica sólida de resina de intercambio catiónico. |
| ES2471340B1 (es) | 2012-12-21 | 2015-08-17 | Laboratorios Rubió, S.A. | Composición farmacéutica oral para fármacos de elevada posología |
| ES2800167T3 (es) * | 2014-12-23 | 2020-12-28 | Ardelyx Inc | Composiciones y métodos para tratar hiperpotasemia |
-
2015
- 2015-12-22 ES ES15828619T patent/ES2800167T3/es active Active
- 2015-12-22 CA CA2971725A patent/CA2971725C/en active Active
- 2015-12-22 NZ NZ732542A patent/NZ732542A/en unknown
- 2015-12-22 EP EP15828619.5A patent/EP3236940B1/en active Active
- 2015-12-22 TW TW104143161A patent/TW201628631A/zh unknown
- 2015-12-22 CN CN201580069983.7A patent/CN107406548B/zh active Active
- 2015-12-22 AR ARP150104260A patent/AR103250A1/es unknown
- 2015-12-22 BR BR112017013264-8A patent/BR112017013264A2/pt not_active Application Discontinuation
- 2015-12-22 US US14/912,682 patent/US9655921B2/en active Active
- 2015-12-22 JP JP2017533536A patent/JP6821571B2/ja active Active
- 2015-12-22 MX MX2017007603A patent/MX373216B/es active IP Right Grant
- 2015-12-22 RU RU2017126229A patent/RU2017126229A/ru unknown
- 2015-12-22 AU AU2015375390A patent/AU2015375390B2/en active Active
- 2015-12-22 KR KR1020177019904A patent/KR102674230B1/ko active Active
- 2015-12-22 WO PCT/US2015/067460 patent/WO2016111855A1/en not_active Ceased
-
2017
- 2017-04-14 US US15/487,967 patent/US20180064751A1/en not_active Abandoned
- 2017-06-01 ZA ZA201703771A patent/ZA201703771B/en unknown
- 2017-06-01 IL IL252603A patent/IL252603A0/en unknown
-
2020
- 2020-07-17 JP JP2020122933A patent/JP7254748B2/ja active Active
-
2022
- 2022-12-22 JP JP2022205560A patent/JP2023027355A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR103250A1 (es) | 2017-04-26 |
| MX373216B (es) | 2020-05-07 |
| US20180064751A1 (en) | 2018-03-08 |
| JP2020172662A (ja) | 2020-10-22 |
| US20160346318A1 (en) | 2016-12-01 |
| KR20170098259A (ko) | 2017-08-29 |
| JP7254748B2 (ja) | 2023-04-10 |
| MX2017007603A (es) | 2017-10-19 |
| JP6821571B2 (ja) | 2021-01-27 |
| ES2800167T3 (es) | 2020-12-28 |
| CA2971725A1 (en) | 2016-07-14 |
| AU2015375390A1 (en) | 2017-06-29 |
| WO2016111855A1 (en) | 2016-07-14 |
| EP3236940B1 (en) | 2020-02-05 |
| ZA201703771B (en) | 2020-11-25 |
| JP2018505262A (ja) | 2018-02-22 |
| EP3236940A1 (en) | 2017-11-01 |
| TW201628631A (zh) | 2016-08-16 |
| CA2971725C (en) | 2024-05-14 |
| BR112017013264A2 (pt) | 2018-02-27 |
| AU2015375390B2 (en) | 2021-06-24 |
| CN107406548B (zh) | 2021-03-02 |
| US9655921B2 (en) | 2017-05-23 |
| JP2023027355A (ja) | 2023-03-01 |
| KR102674230B1 (ko) | 2024-06-11 |
| NZ732542A (en) | 2023-02-24 |
| IL252603A0 (en) | 2017-07-31 |
| CN107406548A (zh) | 2017-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017126229A (ru) | Композиции и способы лечения гиперкалиемии | |
| AU2005231383B2 (en) | Ion binding compositions | |
| US2914444A (en) | Cellulosic hemostatic composition | |
| JP2017218454A5 (enExample) | ||
| JPH0678425B2 (ja) | 重合体の新規製造法 | |
| AU2018206706B2 (en) | Ion binding polymers and uses thereof | |
| JP2009543869A (ja) | アミンデンドリマー | |
| JP2018505262A5 (enExample) | ||
| SHACKELFORD et al. | The aberrantly positioned thymus: a cause of mediastinal or neck masses in children | |
| FI72652B (fi) | Foerfarande foer framstaellning av ett syraneutraliserande medel, som baserar sig pao magnesiumaluminiumhydroxid. | |
| JP2009197149A5 (enExample) | ||
| Stewart | Pleural effusion localized in an interlobar space: Report of a case of heart failure together with autopsy | |
| CN101730704B (zh) | S-腺苷甲硫氨酸的稳定的盐及其制备方法 | |
| JP7730320B2 (ja) | 低分子を捕捉するための高分子組成物 | |
| JP5277965B2 (ja) | ナトリウム吸収阻害剤、カリウム吸収阻害剤およびリン吸収阻害剤、並びにそれを含む予防剤、治療剤および食品 | |
| CN116120201A (zh) | 一种改进的碘比醇合成方法 | |
| CN108114309B (zh) | 一种醛基葡聚糖/蒙脱土复合快速止血材料及其制备方法 | |
| JP2003226648A (ja) | 高リン血症治療剤 | |
| SU1169660A1 (ru) | Рентгеноконтрастное средство | |
| Bobra | Chronic empyema due to Salmonella oranienburg: complication of an old chest wound | |
| JP5277964B2 (ja) | 架橋セルロース誘導体の金属塩 | |
| Sigstad et al. | TERTIARY HYPERPARATHYROIDISM: Report of a Case | |
| JPS5938205B2 (ja) | 肺気腫治療剤 | |
| JP2005139414A (ja) | リン酸吸着剤 | |
| JPH0564126B2 (enExample) |